论文部分内容阅读
目的：观察美宝胃肠胶囊(GIC)治疗消化性溃疡的近期临床疗效。方法：根据自愿原则,将60例消化性溃疡患者(7例为复合型溃疡)分成治疗组和对照组,治疗组口服美宝胃肠胶囊,对照组口服洛赛克、阿莫西林和甲硝唑片。主要观察指际为临床症状改善程度(胃痛分级),胃镜检查结果。结果：美宝胃肠胶囊治疗组胃痛显效率为80．0%,有效率为16．7,显效与有效合并率为96．7%,对照组显效与有效合并率为93．3%；治疗组胃镜检查治愈率为76．5%,对照组为69．7%。结论：美宝胃肠胶囊对消化性溃疡的近期临床疗效已达到目前国内现行疗法水平,值得临床推广应用。
Objective: To observe the recent clinical efficacy of MEBO Gastrointestinal Capsule (GIC) in the treatment of peptic ulcer. Methods: According to the voluntary principle, 60 patients with peptic ulcer (7 patients with complex ulcer) were divided into treatment group and control group, the treatment group oral MEBO Gastrointestinal Capsule, the control group oral administration of Losec, amoxicillin and methylnitrite Azole tablets. The main observation refers to the improvement of clinical symptoms (stomachache grade), endoscopy results. Results: The effective rate of Stomach pain in MEBO Gastrointestinal Capsule group was 80.0%, the effective rate was 16.7, the effective and effective combined rate was 96.7%, and the effective and effective rate in control group was 93.3% Group gastroscopy cure rate was 76.5%, control group was 69.7%. Conclusion: The recent clinical curative effect of MEBO Gastrointestinal Capsule on peptic ulcer has reached the current domestic level of therapy and is worthy of clinical application.